The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $11.54

Today's change+0.22 +1.94%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $11.54

Today's change+0.22 +1.94%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Nektar Therapeutics up sharply

Nektar Therapeutics closed up sharply Friday, rallying (U.S.)$0.22 or 1.94% to (U.S.)$11.54. Over the last five days, shares have lost 3.35% and are down 31.51% for the last year to date. This security has underperformed the S&P 500 by 4.93% during the last year.

Key company metrics

  • Open(U.S.) $11.55
  • Previous close(U.S.) $11.32
  • High(U.S.) $11.62
  • Low(U.S.) $11.28
  • Bid / Ask-- / --
  • YTD % change-31.51%
  • Volume1,097,412
  • Average volume (10-day)2,478,316
  • Average volume (1-month)2,298,355
  • Average volume (3-month)1,721,324
  • 52-week range(U.S.) $9.16 to (U.S.) $17.55
  • Beta1.76
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.57
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-34.47%

Although this company's net profit margin is negative, it is above the industry average and implies that Nektar Therapeutics is operating more effectively than other companies in the industry.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue602310920
Total other revenue--------
Total revenue602310920
Gross profit531210013
Total cost of revenue71186
Total operating expense60666657
Selling / general / administrative10101012
Research & development43454738
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income0-4343-37
Interest income (expense), net non-operating-9-9-9-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-8-5234-47
Income after tax-8-5334-46
Income tax, total000-1
Net income-8-5334-46
Total adjustments to net income--------
Net income before extra. items-8-5334-46
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-8-5334-46
Inc. avail. to common incl. extra. items-8-5334-46
Diluted net income-8-5334-46
Dilution adjustment--------
Diluted weighted average shares133132136129
Diluted EPS excluding extraordinary itemsvalue per share-0.06-0.400.25-0.35
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.06-0.400.25-0.35